Neuro-Oncology News

National Cancer Prevention Month, established by a U.S. Senate resolution and observed every February since 2004, is intended to draw attention to the fact that approximately 70% of malignancies may be prevented through diet or other lifestyle changes.

Jeff Vacirca, MD, FACP, CEO and managing director of clinical research at New York Cancer Specialists in Long Island, N.Y., has been elected president of Community Oncology Alliance for the 2017-2018 term.

Physicians’ willingness to communicate with patients about the cost of cancer care appeared associated with improved patient satisfaction and lower out-of-pocket expenses.

Survivors of childhood cancer who received high-dose neurotoxic treatments while children or adolescents were less likely to have had intercourse, be in a relationship or have children compared with those never diagnosed with cancer, according to a study published in Cancer.

World Cancer Day — which will be observed today — was founded by the Union for International Cancer Control to raise awareness of cancer, and to emphasize the importance of prevention, detection and treatment.

“Robust” federal funding is needed to build on recent advances in cancer research, ASCO’s senior vice president and chief medical officer, Richard L. Schilsky, MD, FASCO, said during a news conference on Capitol Hill on Wednesday.

For the second year in a row, ASCO has named immunotherapy as its cancer advance of the year, according to “Clinical Cancer Advances 2017: ASCO’s Annual Report on Progress Against Cancer.”

Patients who underwent surgery for stage IV cancer experienced high rates of hospital readmissions, referrals to extended care facilities, morbidity and mortality, according to study results published in PLOS One.

Premature death rates in the United States differ by race and ethnicity, showing a decline among Hispanics, blacks and Asian/Pacific Islanders and an increase among whites and American Indian/Alaska Natives between 1999 to 2014, according to a news release issued by the NIH.

A subgroup of patients with glioblastoma and highly vascularized tumors experienced an OS that was about 1 year longer when given targeted antiangiogenic treatments, according to a Stanford University School of Medicine retrospective study published in Neuro-Oncology.